KR EN

R&D Projects

Introduction of Pipeline

The Daewoong Pharmaceutical R&D center is focusing on research and development in fields with high market demands such as chronic and orphan diseases, intractable diseases and improving quality of life to provide innovative new drugs (NCE, biologics), stem cell therapy and incrementally modified drugs for patients.
Innovative
new drugs
Gastroesophageal reflux disease drugs
Diabetes drugs/Obesity drugs
Fibrosis drugs
Autoimmunity drugs
(Targeted, Immuno-) Cancer drugs
Biologics &
Stem Cell Therapy
Musculoskeletal disorders treatment
Dry eye treatment
Immuno-oncology anti-cancer therapy
Stem cell therapy
Incrementally
Modified Drugs (IMD)
Development of complex/sustained IMD for all treatment groups
Long-acting hormone therapy injections
Hormonal microneedle transdermal treatment
Long-Acting Injectable Drugs product for shizophrenia/Infection/Obesity Treatment

R&D Projects

  • DWP216262
    TEAD1/2 mesothelioma, NSCLC
  • Bersiporocin Systemic sclerosis
  • Bersiporocin Diabetic kidney disease
  • DWP219 Post-operative pain
  • DWP820S011 Retinitis pigmentosa
  • DWP715
    Pancreatitis
  • DWP817S004 Sarcopenia
  • DWP457 Long-acting Insulin
  • DWP714 Cartilage regeneration
  • DWP713 Dermal tissue regeneration
  • Novosis-putty
    Spinal fusion
  • DWP305401 Ulcerative colits
  • Bersiporocin Idiopathic pulmonary fibrosis
  • DWP708 ERSE
  • Furestem-RA
    Rheumatoid arthritis
  • Fexuprazan Maintenance of healing of erosive esophagitis
  • Fexuprazan Prevention of NSAIDs induced peptic ulcer
  • Enavogliflozin + insulin
    Type 2 diabetes
  • HL036 Dry eye syndrome
Fexuprazan (NDA)
Gastroesophageal reflux disease Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘Fexuprazan’ is a next-generation drug for gastroesophageal reflux disease with P-CAB mechanism that submitted a drug applcation to the Ministry of Food and Drug Safety (MFDS) after completing domestic phase 3 clinical trials. Fexuprazan is a treatment for gastroesophageal reflux disease that reversibly blocks proton pumps from secreting gastric acid in the stomach.
DWP213388
Autoimmune disease
(Systemic Lupus Erythematosus, Rheumatoid arthritis, Chronic spontaneous urticaria) First-in-Class World's First Innovative New Drug Pipeline
‘DWP213388’ is an oral dosage form of another autoimmune disease drug candidate with a mechanism that selectively suppresses ITK (Interleukin-2-inducible T-cell kinase) and BTK (Bruton's tyrosine kinase), which are targets involved in activating immune cells (T cell and B cell). We are striving to develop a leading global drug to treat patients with Autoimmune & inflammatory disease in which effective treatment options are insufficient.
Enavogliflozin
SGLT2 Diabetes Best-in-Class - New drug pipeline being developed with the goal of best new drugs in series
‘Enavogliflozin’ shows better effect and longer duration than existing products through a SGLT2 suppression mechanism for treatment of type 2 diabetes, and Enavogliflozin is approved NDA in November 2022, and launched it in 2023.
DWP17061
Arthritis Pain First-in-Class World's First Innovative New Drug Pipeline
‘DWP17061’ is a treatment for chronic pain being developed with indication for arthritis and it blocks Nav1.7, a sodium channel.
DWP212525
Autoimmune disease (Pemphigus, rheumatoid arthritis) First-in-Class World's First Innovative New Drug Pipeline
‘DWP212525’ is an oral dosage form autoimmune disease treatment candidate that selectively suppresses JAK3 and TFK involved in activating cells of the immune system (T cell and B cell). We are currently focusing on research to develop various autoimmune disease treatments for pemphigus for which an effective treatment is yet nonexistent and Rheumatoid Arthritis
DWN12088
Idopathic Pulmonary Fibrosis
Systemic sclerosis First-in-Class - New drug pipeline being developed for the first time in the world
‘DWN12088’ is the first pulmonary fibrosis drug being developed in the world and it is a first-in-class pulmonary fibrosis drug with a new mechanism that suppresses excessive generation of collagen, a cause of pulmonary fibrosis, by reducing the action of Prolyl-tRNA synthetase (PRS) protein. It was selected as a supported project by the pan-government new drug development team in March 2019 and was designated as a orphan drug by the US FDA in August.

Stem cell therapy

DW-MSC [mesenchymal stem cell]

DW-MSC [mesenchymal stem cell] is under development as a drug for intractable and rare diseases and degenerative diseases as well as a genetic delivery platform to strengthen stem cell functions. As a stem cell therapy, DW-MSC is being developed with indications for acute pancreatitis, stroke, dementia, cerebral atrophy, and idiopathic pulmonary fibrosis. ‘DW-MSC’ is the 1st mass production available stem cell line developed in Korea which has a high competitiveness for commercialization. Daewoong aims to develop a best-in-class stem cell therapy by applying Cell & Gene technologies to optimize its functions under the name of “Smart Stem Cell”

Incrementally Modified Drugs (IMD)

Development of incrementally modified drugs based on future-oriented platforms

Daewoong Pharmaceutical is continuously developing new products of 2-in-1, 3-in-1, 4-in-1 combination drugs, multi-delivery sustained release oral forms and long-acting depot injections by using a platform technology (oral dosage forms such as core tablets, multi-layer tablets, multi-filling capsules, and long acting depot injections based on microsphere/nano technology). We, also, are working on life cycle extension of key products that form the brand image of Daewoong Pharmaceutical.